CHMP recommends approval of Novo Nordisk's hemophilia drug for postpartum bleeding
The European Medicines Agency expert committee, the CHMP, has recommended that the indication for Novo Nordisk’s hemophilia drug Novoseven is extended to include women suffering from severe hemorrhaging after giving birth.
by christopher due karlsson, translated by daniel pedersen
On Friday, Novo Nordisk has announced that the European Medicines Agency’s (EMA) expert committee, the CHMP, has adopted a positive opinion of Novoseven as a treatment for severe postpartum hemorrhage, a company press release reports.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.